ReviewMedical review (2021)2022
Asymptomatic and pre-symptomatic infection in Coronavirus Disease 2019 pandemic.
Review in Medical review (2021), 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
18 citing papers in PubMed, 34 citations in OpenAlex.
- Selective Wettability-Driven Evaporation-Enhanced Redox Cycling for Robust and Ultrasensitive Detection of Viral Particles.Small methods · 2026Article
- Detection of SARS-CoV-2 RNA on air purifier filters in university spaces without symptomatic or confirmed cases.Aerosol science and technology : the journal of the American Association for Aerosol Research · 2025Article
- SARS-CoV-2 mRNA Vaccine Effectiveness in the Borriana COVID-19 Cohort: A Prospective Population-Based Cohort Study.Epidemiologia (Basel, Switzerland) · 2025Article
- The dual threat: exploring the emergence of human metapneumovirus and SARS-CoV-2 coinfections in respiratory infections.3 Biotech · 2025Review
- Dual threat: Susceptibility mechanisms and treatment strategies for COVID-19 and bacterial co-infections.Computational and structural biotechnology journal · 2025Review
- Mpox in sports: A comprehensive framework for anticipatory planning and risk mitigation in football based on lessons from COVID-19.Biology of sport · 2024Review
- Asymptomatic Children as a Missing Link in Preventing COVID-19 Transmission.Journal of research in health sciences · 2024Article
- Small Molecule Drugs Targeting Viral Polymerases.Pharmaceuticals (Basel, Switzerland) · 2024Review
- SARS-CoV-2 infection prevalence and associated factors among primary healthcare workers in France after the third COVID-19 wave.Scientific reports · 2024Article
- Cohort profile: follow-up of a household cohort throughout five epidemic waves of SARS-CoV-2 in Rio de Janeiro, Brazil.Cadernos de saude publica · 2024Article
- Seroprevalence of SARS-CoV-2 antibodies among healthcare workers in Dutch hospitals after the 2020 first wave: a multicentre cross-sectional study with prospective follow-up.Antimicrobial resistance and infection control · 2023Article
- Vaccine Effectiveness Against Severe Acute Respiratory Syndrome Coronavirus 2 Delta and Omicron Infection and Infectiousness Within Households in the Netherlands Between July 2021 and August 2022.The Journal of infectious diseases · 2023Article
- Assessing the Impact of Vaccination on the Dynamics of COVID-19 in Africa: A Mathematical Modeling Study.Vaccines · 2023Article
- Asymptomatic and Mild SARS-CoV-2 Infections in a Hungarian Outpatient Cohort in the First Year of the COVID-19 Pandemic.Tropical medicine and infectious disease · 2023Article
- Association between SARS-CoV-2 Viral Load and Patient Symptoms and Clinical Outcomes Using Droplet Digital PCR.Viruses · 2023Article
- Negative association between ascaris lumbricoides seropositivity and Covid-19 severity: insights from a study in Benin.Frontiers in immunology · 2023Article
- Comparison of plasma mitochondrial DNA copy number in asymptomatic and symptomatic COVID-19 patients.Frontiers in microbiology · 2023Article
- Prognosis of COVID-19 in the middle eastern population, knowns and unknowns.Frontiers in microbiology · 2022Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
With the presence of Coronavirus Disease 2019 (COVID-19) asymptomatic infections detected, their proportion, transmission potential, and other aspects such as immunity and related emerging challenges have attracted people's attention. We have found that based on high-quality research, asymptomatic infections account for at least one-third of the total cases, whereas based on systematic review and meta-analysis, the proportion is about one-fifth. Evaluating the true transmission potential of asymptomatic cases is difficult but critical, since it may affect national policies in response to COVID-19. We have summarized the current evidence and found, compared with symptomatic cases, the transmission capacity of asymptomatic individuals is weaker, even though they have similar viral load and relatively short virus shedding duration. As the outbreak progresses, asymptomatic infections have also been found to develop long COVID-19. In addition, the role of asymptomatic infection in COVID-19 remains to be further revealed as the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) variants continue to emerge. Nevertheless, as asymptomatic infections transmit the SARS-CoV-2 virus silently, they still pose a substantial threat to public health. Therefore, it is essential to conduct screening to obtain more knowledge about the asymptomatic infections and to detect them as soon as possible; meanwhile, management of them is also a key point in the fight against COVID-19 community transmission. The different management of asymptomatic infections in various countries are compared and the experience in China is displayed in detail.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.